IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triplenegative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for AntiPD1/PD-L1 Treatment
Read more about this trial →← Back to available clinical trials
